• 1. Essential effect of the electrolyte on the mechanical and chemical degradation of LiNi0.8Co0.15Al0.05O2 cathodes upon long-term cycling??
  Xiaoming Liu,Zachary D. Hood,Wangda Li,Donovan N. Leonard,Arumugam Manthiram,Miaofang Chi J. Mater. Chem. A, 2021,9, 2111-2119
• 2. Ester-directed orthogonal dual C–H activation and ortho aryl C–H alkenylation via distal weak coordination?
  Manickam Bakthadoss,Tadiparthi Thirupathi Reddy,Vishal Agarwal,Duddu S. Sharada Chem. Commun., 2022,58, 1406-1409
• 3. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293
• 4. Excimer and exciplex formation in a pair of bright phosphorescent isomers constructed from Cu3(pyrazolate)3 and Cu3I3 coordination luminophores?
  Shun-Ze Zhan,Mian Li,Xiao-Ping Zhou,Dan Li,Seik Weng Ng RSC Adv., 2011,1, 1457-1459
• 5. Enabling shape memory and healable effects in a conjugated polymer by incorporating siloxane via dynamic imine bond?
  Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095

Recent Advances in the Study of (R)-Methyl 2-amino-3-cyclopentylpropanoate (CAS: 1212129-47-9)

The compound (R)-Methyl 2-amino-3-cyclopentylpropanoate (CAS: 1212129-47-9) has recently garnered significant attention in the field of chemical biology and pharmaceutical research. This chiral amino acid derivative is recognized for its potential as a key intermediate in the synthesis of bioactive molecules, particularly in the development of novel therapeutics targeting neurological disorders and metabolic diseases. Recent studies have focused on optimizing its synthetic pathways, elucidating its pharmacological properties, and exploring its applications in drug discovery.

One of the most notable advancements in the study of (R)-Methyl 2-amino-3-cyclopentylpropanoate is the development of more efficient enantioselective synthesis methods. Researchers have reported improved catalytic systems that enhance the yield and purity of the (R)-enantiomer, which is critical for its application in asymmetric synthesis. These methods often employ chiral catalysts or biocatalysts, such as engineered enzymes, to achieve high stereoselectivity. The optimization of these synthetic routes not only reduces production costs but also minimizes environmental impact, aligning with the principles of green chemistry.

In addition to synthetic improvements, recent pharmacological studies have explored the compound's potential as a modulator of neurotransmitter systems. Preliminary in vitro and in vivo experiments suggest that (R)-Methyl 2-amino-3-cyclopentylpropanoate may interact with GABAergic and glutamatergic pathways, making it a candidate for the treatment of anxiety, epilepsy, and other central nervous system disorders. However, further research is needed to fully characterize its mechanism of action and evaluate its safety profile.

Another area of interest is the application of (R)-Methyl 2-amino-3-cyclopentylpropanoate in the design of peptide-based therapeutics. Its unique cyclopentyl side chain provides conformational rigidity, which can enhance the stability and bioavailability of peptide drugs. Recent studies have demonstrated its utility in the synthesis of cyclic peptides and peptidomimetics, which are increasingly being explored as alternatives to traditional small-molecule drugs.

Despite these promising developments, challenges remain in the large-scale production and clinical translation of (R)-Methyl 2-amino-3-cyclopentylpropanoate. Issues such as scalability, regulatory compliance, and intellectual property protection must be addressed to fully realize its potential. Collaborative efforts between academia and industry will be essential to overcome these hurdles and advance the compound from the laboratory to the clinic.

In conclusion, (R)-Methyl 2-amino-3-cyclopentylpropanoate (CAS: 1212129-47-9) represents a versatile and promising building block in medicinal chemistry. Recent research has highlighted its potential in drug discovery, particularly in the areas of neuroscience and peptide therapeutics. Continued investigation into its synthetic, pharmacological, and clinical properties will be crucial for unlocking its full therapeutic value.

• 18869-43-7(methyl leucinate)
• 763078-53-1(Methyl 2-Amino-2-cyclopentylacetate)
• 14328-62-2((S)-Methyl 2-amino-2-cyclopentylacetate hydrochloride)
• 1191996-99-2((S)-Methyl 2-amino-3-cyclopentylpropanoate hydrochloride)
• 1169946-94-4((S)-Methyl 2-amino-3-cyclopentylpropanoate)
• 23032-21-5((R)-Methyl 2-amino-4-methylpentanoate)
• 2666-93-5(methyl (2S)-2-amino-4-methylpentanoate)
• 88824-61-7(methyl 2-amino-5-methylhexanoate)
• 1119833-62-3(Methyl 2-amino-3-cyclopentylpropanoate)
• 763877-90-3(L-Norleucine,5-methyl-, methyl ester)